Comparative Effectiveness of Novel vs Established Therapies in Obstructive Hypertrophic Cardiomyopathy (HOCM): Insights From a US Electronic Health Records (EHR) Study
Author(s)
Shikha Anand, MBBS1, Solomon Sundaram, MBBS MBA1, Mohini Rastogi, Msc2, Ankita Gupta, Msc1, Simran Pattanaik, MHA, BDS1, Arunima Sachdev, MA1, Abhimanyu Roy, MBA1, Abhinav Nayyar, MBBS, MBA1, Ina Kukreja, MBA, PT1, Vikash Kumar Verma, MBA, PharmD1, Louis Brooks Jr, MA3, Rahul Goyal, BS Tech4, Marissa Seligman, BS Pharma5.
1Optum, Gurgaon, India, 2Optum, Noida, India, 3Optum, Bloomsbury, NJ, USA, 4Optum, Phoenix, AZ, USA, 5Optum, Boston, MA, USA.
1Optum, Gurgaon, India, 2Optum, Noida, India, 3Optum, Bloomsbury, NJ, USA, 4Optum, Phoenix, AZ, USA, 5Optum, Boston, MA, USA.
Presentation Documents
OBJECTIVES: The objective of this retrospective study is to evaluate the effectiveness of novel compared to the established therapy in patients with HOCM
METHODS: De-identified Optum Market Clarity databases was used for the timeframe July 2020 to July 2023. Prevalent HOCM patients were identified from July 2020 to June 2022. Index period was from July 2022 to July 2023 with index event being the first prescription for novel therapy. Inclusion criteria involved patients >= 18 years who had a claim for HOCM (ICD10 I42.1). Patients below 18 years, patients who opted for HOCM specific surgeries for symptomatic relief, and patients with medication adherence below 80% were excluded. The study featured two cohorts: one receiving established treatment and the other receiving a combination of established and novel therapies, matched at a 1:2 ratio by age and gender using propensity score matching (PSM).
RESULTS: The prevalent pool consisted of 27,937 HOCM patients diagnosed between July 2020 and June 2022. The majority of patients (23,206) were aged above 50 years, while the lowest prevalence was observed in patients between 18 to 30 years (816). No differences in gender prevalence were observed. Among the two cohorts, established therapy cohort had 13,540 patients whereas novel therapy cohort had 267 patients. After applying PSM, 137 patients were eligible for analysis. Further, we would explore structured data and clinical notes to compare changes in ejection fraction, NYHA class, and improvements in signs and symptoms as breathlessness, fatigue, and heart failure between the two cohorts in the follow up period.
CONCLUSIONS: Insights gained from this study will contribute to a broader understanding of treatment strategies for HOCM, potentially guiding clinical decisions towards improved patient outcomes and enhanced quality of life.
METHODS: De-identified Optum Market Clarity databases was used for the timeframe July 2020 to July 2023. Prevalent HOCM patients were identified from July 2020 to June 2022. Index period was from July 2022 to July 2023 with index event being the first prescription for novel therapy. Inclusion criteria involved patients >= 18 years who had a claim for HOCM (ICD10 I42.1). Patients below 18 years, patients who opted for HOCM specific surgeries for symptomatic relief, and patients with medication adherence below 80% were excluded. The study featured two cohorts: one receiving established treatment and the other receiving a combination of established and novel therapies, matched at a 1:2 ratio by age and gender using propensity score matching (PSM).
RESULTS: The prevalent pool consisted of 27,937 HOCM patients diagnosed between July 2020 and June 2022. The majority of patients (23,206) were aged above 50 years, while the lowest prevalence was observed in patients between 18 to 30 years (816). No differences in gender prevalence were observed. Among the two cohorts, established therapy cohort had 13,540 patients whereas novel therapy cohort had 267 patients. After applying PSM, 137 patients were eligible for analysis. Further, we would explore structured data and clinical notes to compare changes in ejection fraction, NYHA class, and improvements in signs and symptoms as breathlessness, fatigue, and heart failure between the two cohorts in the follow up period.
CONCLUSIONS: Insights gained from this study will contribute to a broader understanding of treatment strategies for HOCM, potentially guiding clinical decisions towards improved patient outcomes and enhanced quality of life.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO47
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)